Page 41 - Planegg News Today

silk polymers AMSilk to accelerate industrial scale-up and expand commercial operations into new markets Munich, May 11, 2021 - AMSilk GmbH ("AMSilk"), the worlds first industrial supplier of synthetic silk biopolymers, today announces the successful closing of a EUR 29 million Series C fundraise. The financing was led by Novo Growth, the growth equity arm of Novo Holdings, with participation from new investors Cargill and E.R. Capital Holdings as well as existing investors MIG Verwaltungs AG ...

DGAP-News: AMSilk raises EUR 29M to accelerate commercialization of its high-performance bio-based silk polymers vom 11.05.2021, 10:22 Uhr Bild: pixabay.com AMSilk raises EUR 29M to accelerate commercialization of its high-performance bio-based silk polymers 11.05.2021 / 10:22 - PRESS RELEASE - silk polymers - AMSilk to accelerate industrial scale-up and expand commercial operations into new markets Munich, May 11, 2021 - AMSilk GmbH ("AMSilk"), the worlds first industrial supplier of synth...

frontMIND Study Evaluating Tafasitamab Combination as a  First-line Treatment for Diffuse Large B-Cell Lymphoma PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as firs...

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma ACCESSWIRE 12 May 2021, 06:05 GMT+10 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituxima...

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma The frontMIND (NCT04824092) trial is a randomized, double-blind, placebo-controlled, global Phase 3 clinical study in previously untreated high-intermediate and high-risk DLBCL patients that is conducted in partnership with the German Lymphoma Association (GLA), the Italian Lymphoma study group and the US Oncol...

DGAP-News: AMSilk GmbH: AMSilk raises EUR 29M to accelerate commercialization of its high-performance bio-based silk polymers AMSilk raises EUR 29M to accelerate commercialization of its high-performance bio-based silk polymers 11.05.2021 / 10:22 ----------- PRESS RELEASE ----------- silk polymers - AMSilk to accelerate industrial scale-up and expand commercial operations into new markets Munich, May 11, 2021 - AMSilk GmbH ("AMSilk"), the worlds first industrial supplier of synthetic silk bi...

MorphoSys AG Reports First Quarter 2021 Results Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) reports financial results for the first quarter of 2021. "For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the ta...

Share: MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil LHuillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil LHuillier brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, with an outstanding track record of success in the commercial development of businesses and partnershi...

MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the...

Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021 DGAP-News: MorphoSys AG / Key word(s): Quarter Results 28.04.2021 / 22:00 Conference Call Alert Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first...